About Emcure
Emcure is a company based in Pune (India) founded in 1983 by Sunil Rajanikant Mehta. Emcure has raised $50 million across 2 funding rounds from investors including Blackstone and Bain Capital Private Equity. The company has 6,730 employees as of March 31, 2024. Emcure has completed 1 acquisition, including International Pharmaceutical Generics. Emcure offers products and services including Formulations and Biologics.
- Headquarter Pune, India
- Employees 6730 as on 31 Mar, 2024
- Founders Sunil Rajanikant Mehta
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Emcure Pharmaceuticals Limited
-
Annual Revenue
$915.21 M (USD)18.61as on Mar 31, 2025
-
Net Profit
$79.71 M (USD)36.76as on Mar 31, 2025
-
EBITDA
$164.34 M (USD)19.23as on Mar 31, 2025
-
Total Equity Funding
$50 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Blackstone
& 1 more
-
Employee Count
6730
as on Mar 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Emcure
Emcure is a publicly listed company on the NSE with ticker symbol EMCURE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Emcure
Emcure offers a comprehensive portfolio of products and services, including Formulations and Biologics.
Formulations are developed and manufactured by Emcure for various therapeutic uses, enabling the provision of affordable healthcare solutions.
Biologics are produced by Emcure for treating complex diseases, including biosimilars and novel therapies that support global health needs.
Funding Insights of Emcure
Emcure has successfully raised a total of $50M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Emcure
Emcure has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Blackstone and Bain Capital Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm managing assets and expanding into equity, credit, and real estate services.
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked |
Investor details for Emcure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emcure
Emcure has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include International Pharmaceutical Generics.
Investment portfolio details for Emcure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Generic drugs are manufactured for international distribution.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Emcure
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Emcure
Detailed financials for Emcure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emcure Comparisons
Peer comparison for Emcure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emcure
Detailed competitors of Emcure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emcure
Complete news archive for Emcure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emcure
Emcure was founded in 1983 and raised its 1st funding round 23 years after it was founded.
Emcure is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Emcure is a funded company, having raised a total of $50M across 2 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Emcure is 6,730.
Annual revenue of Emcure is $915.21M as on Mar 31, 2025.
Emcure was founded in 1983 in Pune, India, within the pharmaceutical sector. Pharmaceutical products are developed, manufactured, and marketed across therapeutic areas such as gynecology, cardiology, oncology, blood disorders, HIV, respiratory, CNS, and anti-infectives. Formulations, biologics, and active pharmaceutical ingredients are also produced. Operations focus on global distribution from the Indian base.
Emcure offers Formulations and Biologics.
Yes, Emcure is publicly traded on NSE under the ticker symbol EMCURE.
Emcure has made 1 acquisition, including International Pharmaceutical Generics.
Emcure has 2 investors. Key investors include Blackstone, and Bain Capital Private Equity.
The ticker symbol of Emcure is EMCURE on NSE.
The valuation of Emcure is $367.12M as of Jul 2006.